What is the best method of nonspecific nephroprotection?

Jürgen Floege

Jürgen Floege, MD, is a professor of medicine, director of the Division of Nephrology and Clinical Immunology at the University Hospital RWTH Aachen, Germany, and Distinguished Fellow of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA).

As of today, can we consider any of the available methods of nonspecific nephroprotection—that is, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), sodium-glucose cotransporter-2 (SGLT-2) inhibitors, or aldosterone receptor inhibitors—superior to others?

I think we have no good comparative studies and there probably will never be any.

It may be that this is a little dependent on the individual. Some patients may have [bigger] activation of the renin-angiotensin system (RAS) than others, but for practical purposes, I think we will go for combination therapy in the future more and more.

And as I said, we will probably start it right away and in parallel to protect as many nephrons as we can. So your question is probably an academic one.

See also

We would love to hear from you

Comments, mistakes, suggestions?

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.